Shannon James Samuel 4

What Happened

• Shannon James Samuel, a director of Xilio Therapeutics, was granted a derivative award (an option) covering 5,000 shares on June 11, 2026. The reported per-share price in the filing is $0.00, resulting in a reported acquisition value of $0.
• This is an award/grant (not an open-market purchase or sale) and does not represent an immediate sale or cash proceeds.

Key Details

• Transaction date: June 11, 2026; Form 4 filed June 12, 2026 (timely).
• Security: derivative option for 5,000 shares; reported price $0.00; reported value $0.
• Shares owned after the transaction: not specified in the excerpted transaction data.
• Footnote: The option vests 100% on the earlier of (i) June 11, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service by the reporting person through the vesting date.
• Filing status: timely (no late-filing indication).

Context

• This is a grant of an option (derivative award) rather than a purchase or sale. Vesting conditions mean Samuel does not immediately receive tradable shares; the award becomes effective only if the vesting conditions are met.
• Awards to directors are common compensation to align interests with shareholders; they do not by themselves indicate immediate buying or selling activity.